Insider Trading activities of Savient Pharmaceuticals Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Savient Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Savient Pharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Savient Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is SVNT. The reporting company's CIK number is 722104.
The total value of stock buying since 2005 is $678,839.
The total value of stock sales since 2005 is $11,758,651.
The total value of stock option exercises since 2005 is $1,571,446.


Go to page:  1   2 
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Savient Pharmaceuticals Inc (SVNT).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2013-05 0 $0 1,020 $581 0 $0
2013-04 0 $0 3,735 $2,763 0 $0
2013-03 0 $0 1,560 $1,450 0 $0
2013-02 0 $0 170,975 $174,551 0 $0
2013-01 0 $0 4,998 $5,264 0 $0
2012-11 0 $0 950 $1,102 0 $0
2012-10 0 $0 3,010 $4,364 0 $0
2012-08 0 $0 8,434 $5,604 0 $0
2012-05 0 $0 10,142 $22,392 0 $0
2012-02 0 $0 7,640 $15,596 0 $0
2012-01 0 $0 17,650 $40,595 0 $0
2011-11 30,000 $71,404 0 $0 0 $0
2011-09 50,500 $205,203 0 $0 0 $0
2011-02 0 $0 8,581 $84,843 0 $0
2011-01 0 $0 2,032 $20,320 0 $0
2010-12 0 $0 1,536 $18,232 0 $0
2010-09 0 $0 0 $0 7,500 $88,597
2010-02 0 $0 15,993 $218,566 0 $0
2009-12 0 $0 10,887 $129,367 0 $0
2009-09 0 $0 29,887 $466,848 7,500 $32,400
2009-05 0 $0 1,179 $6,791 0 $0
2009-02 0 $0 16,237 $93,858 0 $0
2009-01 0 $0 2,230 $13,605 0 $0
2008-12 0 $0 25,100 $120,859 0 $0
2008-06 0 $0 12,159 $313,705 15,659 $149,288
2008-05 0 $0 18,232 $434,998 0 $0
2008-04 0 $0 25,140 $503,324 10,000 $31,550
2008-03 0 $0 12,375 $283,002 12,375 $77,061
2008-02 0 $0 55,693 $1,136,588 22,375 $99,760
2008-01 0 $0 172,545 $3,888,731 149,375 $431,946
2007-12 0 $0 78,103 $1,357,513 48,333 $238,331
2007-11 0 $0 10,000 $141,355 10,000 $125,082
2007-10 0 $0 45,855 $707,602 45,855 $297,431
2007-05 0 $0 1,220 $17,504 0 $0
2007-04 0 $0 15,218 $182,904 0 $0
2007-03 0 $0 78,504 $985,095 0 $0
2007-02 0 $0 13,192 $190,895 0 $0
2007-01 0 $0 2,096 $31,389 0 $0
2006-12 0 $0 900 $10,512 0 $0
2006-09 6,000 $38,394 0 $0 0 $0
2006-08 6,000 $35,010 0 $0 0 $0
2006-07 6,000 $31,590 0 $0 0 $0
2006-06 3,000 $17,502 0 $0 0 $0
2006-05 10,000 $54,910 0 $0 0 $0
2006-04 0 $0 21,464 $125,983 0 $0
2005-06 11,800 $39,371 0 $0 0 $0
2005-05 60,000 $185,455 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Savient Pharmaceuticals Inc insiders (SVNT)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2013-05-22 Ferrari Louis (President and CEO) Sale 1,020 .57 581
2013-04-30 Bahrt Kenneth (SVP, Chief Medical Officer) Sale 1,250 .74 925
2013-04-30 Crowley Richard (EVP, Chief Operating Officer) Sale 2,485 .74 1,838
2013-03-06 Gionco David (Group VP & Chief Acct. Officer) Sale 1,560 .93 1,450
2013-02-25 Ferrari Louis (President and CEO) Sale 375 .99 371
2013-02-04 Bahrt Kenneth (SVP, Chief Medical Officer) Sale 29,000 1.02 29,724
2013-02-04 Ferrari Louis (President and CEO) Sale 62,200 1.02 63,132
2013-02-04 Crowley Richard (EVP, Biopharmaceutical Ops) Sale 48,900 1.03 50,367
2013-02-04 Yachmetz Philip K (SVP, General Counsel) Sale 30,500 1.02 30,957
2013-01-31 Bahrt Kenneth (SVP, Chief Medical Officer) Sale 1,300 1.03 1,339
2013-01-31 Crowley Richard (EVP, Biopharmaceutical Ops) Sale 2,415 1.02 2,463
2013-01-14 Yachmetz Philip K (SVP, General Counsel) Sale 1,283 1.14 1,462
2012-11-26 Ferrari Louis (President and CEO) Sale 950 1.16 1,102
2012-10-31 Bahrt Kenneth (SVP, Chief Medical Officer) Sale 1,000 1.45 1,450
2012-10-31 Crowley Richard (EVP, Biopharmaceutical Ops) Sale 2,010 1.45 2,914
2012-08-22 Ferrari Louis (President and CEO) Sale 984 1.00 985
2012-08-02 Crowley Richard (EVP, Biopharma Operatiotions) Sale 2,500 .62 1,550
2012-08-01 Bahrt Kenneth (SVP, Chief Medical Officer) Sale 4,950 .62 3,069
2012-05-22 Ferrari Louis (EVP, North American Commerical) Sale 942 .82 772
2012-05-01 Crowley Richard (EVP Biopharmaceutical Operatio) Sale 9,200 2.35 21,620
2012-02-22 Ferrari Louis (EVP, North American Commerical) Sale 4,100 2.06 8,446
2012-02-14 Yachmetz Philip K (SVP, General Counsel) Sale 3,540 2.02 7,150
2012-01-03 Johnson John (Chief Executive Officer) Sale 17,650 2.30 40,595
2011-11-21 Ferrari Louis (SVP, North American Commerical) Buy 4,000 2.29 9,160
2011-11-21 Johnson John (CEO & President) Buy 5,000 2.30 11,500
2011-11-21 Crowley Richard (EVP Biopharmaceutical Operatio) Buy 3,000 2.53 7,589
2011-11-18 Johnson John (CEO & President) Buy 11,000 2.32 25,520
2011-11-18 Zuerblis Kenneth J (EVP, Chief Financial Officer) Buy 2,000 2.34 4,690
2011-11-16 Bahrt Kenneth (SVP, Chief Medical Officer) Buy 5,000 2.59 12,945
2011-09-16 Johnson John (CEO & President) Buy 26,500 4.10 108,517
2011-09-16 Yachmetz Philip K (SVP, General Counsel) Buy 7,000 4.13 28,910
2011-09-15 Heller Alan L (Director) Buy 7,500 3.99 29,925
2011-09-15 Zuerblis Kenneth J (EVP, Chief Financial Officer) Buy 4,000 4.05 16,187
2011-09-14 Bahrt Kenneth (SVP, Chief Medical Officer) Buy 3,000 3.96 11,871
2011-09-14 Johnson John (CEO & President) Buy 1,500 3.88 5,823
2011-09-14 Zuerblis Kenneth J (EVP, Chief Financial Officer) Buy 1,000 3.97 3,970
2011-02-14 Hamelin Paul (President) Sale 5,371 9.89 53,119
2011-02-14 Yachmetz Philip K (SVP, General Counsel) Sale 3,210 9.88 31,724
2011-01-24 Gionco David (Group VP & CFO) Sale 2,032 10.00 20,320
2010-12-20 Gionco David (Group VP & CFO) Sale 1,536 11.87 18,232
2010-09-02 Thompson Virgil (Director) Option Ex 7,500 11.81 88,597
2010-02-16 Gionco David (Group VP & CFO) Sale 1,253 13.81 17,300
2010-02-16 Hamelin Paul (President) Sale 6,925 13.80 95,551
2010-02-16 Yachmetz Philip K (SVP, General Counsel) Sale 5,778 13.80 79,713
2010-02-09 Gionco David (Group VP & CFO) Sale 2,037 12.76 26,002
2009-12-21 Gionco David (VP, CFO) Sale 1,511 12.95 19,561
2009-12-17 Hamelin Paul (President) Sale 1,777 5.77 10,251
2009-12-09 Hamelin Paul (President) Sale 1,981 13.36 26,476
2009-12-09 Yachmetz Philip K (SVP, General Counsel) Sale 5,418 13.31 72,118
2009-12-09 Clement Christopher G (Other) Sale 200 4.81 961
2009-09-15 Gionco David (Group VP, CFO) Sale 7,500 15.95 119,625
2009-09-15 Gionco David (Group VP, CFO) Option Ex 7,500 4.32 32,400
2009-09-15 Yachmetz Philip K (SVP, General Counsel) Sale 3,750 16.25 60,937
2009-09-14 Gionco David (Group VP, CFO) Sale 10,887 15.36 167,224
2009-09-14 Yachmetz Philip K (SVP, General Counsel) Sale 3,750 15.75 59,062
2009-09-11 Hamelin Paul (President) Sale 4,000 15.00 60,000
2009-05-26 Hamelin Paul (President) Sale 1,179 5.76 6,791
2009-02-17 Lamm Robert (Other) Sale 1,548 5.71 8,839
2009-02-17 Hayden Brian J (Other) Sale 3,441 5.76 19,837
2009-02-17 Yachmetz Philip K (SVP - General Counsel) Sale 5,868 5.73 33,629
2009-02-17 Horowitz Zebulun D (SVP - Chief Medical Officer) Sale 5,380 5.86 31,553
2009-01-22 Lamm Robert (SVP, Quality & Reg. Affairs) Sale 2,230 6.10 13,605
2008-12-09 Hamelin Paul (President) Sale 2,515 4.77 11,996
2008-12-09 Yachmetz Philip K (SVP - General Counsel) Sale 6,400 4.86 31,104
2008-12-09 Horowitz Zebulun D (SVP - Chief Medical Officer) Sale 5,050 4.82 24,366
2008-12-09 Clement Christopher G (Other) Sale 9,225 4.79 44,187
2008-12-08 Lamm Robert (SVP, Quality & Reg. Affairs) Sale 1,910 4.82 9,206
2008-06-24 Hamelin Paul (SVP, Commercial Operations) Sale 1,231 25.25 31,082
2008-06-24 Hamelin Paul (SVP, Commercial Operations) Option Ex 1,231 5.11 6,290
2008-06-23 Hamelin Paul (SVP, Commercial Operations) Sale 5,000 25.75 128,750
2008-06-23 Hamelin Paul (SVP, Commercial Operations) Option Ex 5,000 12.11 60,550
2008-06-19 Hamelin Paul (SVP, Commercial Operations) Sale 1,928 24.89 47,993
2008-06-19 Hamelin Paul (SVP, Commercial Operations) Option Ex 1,928 12.11 23,348
2008-06-03 Thompson Virgil (Director) Option Ex 7,500 7.88 59,100
2008-06-02 Klein Joseph Iii (Director) Sale 4,000 26.47 105,880
2008-05-27 Klein Joseph Iii (Director) Sale 4,000 24.07 96,280
2008-05-23 Hamelin Paul (SVP, Commercial Operations) Sale 1,232 24.09 29,678
2008-05-19 Klein Joseph Iii (Director) Sale 4,000 22.67 90,680
2008-05-12 Klein Joseph Iii (Director) Sale 4,000 24.59 98,360
2008-05-06 Hayden Brian J (SVP, Chief Financial Officer) Sale 5,000 24.00 120,000
2008-04-14 Yachmetz Philip K (EVP, Chief Business Officer) Sale 3,785 19.00 71,918
2008-04-14 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 3,785 19.05 72,092
2008-04-14 Clement Christopher G (President & CEO) Sale 7,570 19.06 144,299
2008-04-02 Conrad Herbert J (Director) Sale 5,000 21.11 105,570
2008-04-02 Conrad Herbert J (Director) Option Ex 5,000 2.48 12,400
2008-04-01 Conrad Herbert J (Director) Sale 5,000 21.89 109,445
2008-04-01 Conrad Herbert J (Director) Option Ex 5,000 3.83 19,150
2008-03-04 Conrad Herbert J (Director) Sale 5,000 23.00 115,000
2008-03-04 Conrad Herbert J (Director) Option Ex 5,000 4.61 23,050
2008-03-03 Hamelin Paul (SVP, Commercial Operations) Sale 2,375 22.78 54,102
2008-03-03 Hamelin Paul (SVP, Commercial Operations) Option Ex 2,375 12.11 28,761
2008-03-03 Conrad Herbert J (Director) Sale 5,000 22.78 113,900
2008-03-03 Conrad Herbert J (Director) Option Ex 5,000 5.05 25,250
2008-02-29 Hayden Brian J (SVP, Chief Financial Officer) Sale 2,279 24.00 54,696
2008-02-28 Hayden Brian J (SVP, Chief Financial Officer) Sale 5,000 24.06 120,295
2008-02-20 Yachmetz Philip K (EVP, Chief Business Officer) Sale 2,455 20.00 49,112
2008-02-15 Hamelin Paul (SVP, Commercial Operations) Sale 1,636 19.92 32,587
2008-02-15 Lamm Robert (SVP, Quality & Reg Affairs) Sale 1,255 20.08 25,195
2008-02-15 Hayden Brian J (SVP, Chief Financial Officer) Sale 2,817 19.98 56,278
2008-02-15 Yachmetz Philip K (EVP, Chief Business Officer) Sale 2,361 20.00 47,231
2008-02-15 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 4,403 19.95 87,844
2008-02-15 Clement Christopher G (President & CEO) Sale 11,112 20.00 222,240
2008-02-04 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 19.86 99,305
2008-02-04 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 4.31 21,549
2008-02-04 Conrad Herbert J (Director) Sale 5,000 20.00 100,000
2008-02-04 Conrad Herbert J (Director) Option Ex 5,000 4.67 23,350
2008-02-01 Hamelin Paul (SVP, Commercial Operations) Sale 2,375 20.00 47,500
2008-02-01 Hamelin Paul (SVP, Commercial Operations) Option Ex 2,375 12.11 28,761
2008-02-01 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 19.56 97,790
2008-02-01 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-02-01 Conrad Herbert J (Director) Sale 5,000 19.30 96,515
2008-02-01 Conrad Herbert J (Director) Option Ex 5,000 2.70 13,500
2008-01-22 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 20.21 101,060
2008-01-22 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-18 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 20.67 103,335
2008-01-18 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-17 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 20.44 102,195
2008-01-17 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-17 Clement Christopher G (President & CEO) Sale 5,000 20.29 101,450
2008-01-17 Clement Christopher G (President & CEO) Option Ex 5,000 2.97 14,850
2008-01-16 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 20.64 103,215
2008-01-16 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-16 Clement Christopher G (President & CEO) Sale 5,000 21.24 106,199
2008-01-16 Clement Christopher G (President & CEO) Option Ex 5,000 2.97 14,850
2008-01-15 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 21.46 107,300
2008-01-15 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-15 Clement Christopher G (President & CEO) Sale 5,000 21.36 106,795
2008-01-15 Clement Christopher G (President & CEO) Option Ex 5,000 2.88 14,375
2008-01-14 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 21.77 108,844
2008-01-14 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-14 Clement Christopher G (President & CEO) Sale 5,000 21.64 108,200
2008-01-14 Clement Christopher G (President & CEO) Option Ex 5,000 2.78 13,899
2008-01-11 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 22.02 110,075
2008-01-11 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-11 Clement Christopher G (President & CEO) Sale 5,000 22.00 109,995
2008-01-11 Clement Christopher G (President & CEO) Option Ex 5,000 2.78 13,899
2008-01-10 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 21.93 109,650
2008-01-10 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-10 Clement Christopher G (President & CEO) Sale 5,000 22.42 112,100
2008-01-10 Clement Christopher G (President & CEO) Option Ex 5,000 2.78 13,899
2008-01-09 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 21.59 107,965
2008-01-09 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-09 Clement Christopher G (President & CEO) Sale 5,000 21.88 109,410
2008-01-09 Clement Christopher G (President & CEO) Option Ex 5,000 2.78 13,899
2008-01-08 Yachmetz Philip K (EVP, Chief Business Officer) Sale 5,000 23.15 115,755
2008-01-08 Yachmetz Philip K (EVP, Chief Business Officer) Option Ex 5,000 2.42 12,100
2008-01-08 Horowitz Zebulun D (SVP, Chief Medical Officer) Sale 5,000 23.14 115,725
2008-01-08 Horowitz Zebulun D (SVP, Chief Medical Officer) Option Ex 5,000 2.52 12,600
2008-01-08 Clement Christopher G (President & CEO) Sale 5,170 23.15 119,690
2008-01-08 Clement Christopher G (President & CEO) Option Ex 2,000 2.78 5,560
Go to page:  1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of SVNT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Savient Pharmaceuticals Inc (symbol SVNT, CIK number 722104) see the Securities and Exchange Commission (SEC) website.